Informações de Corcept Therapeutics Inc

Mais detalhes de Corcept Therapeutics Inc Empresa

Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.



Código da empresaCORT

Nome da EmpresaCorcept Therapeutics Inc

Data de listagemApr 15, 2004

CEODr. Joseph K. Belanoff, M.D.

Número de funcionários500

Tipo de títulosOrdinary Share

Fim do ano fiscalApr 15

Endereço101 Redwood Shores Parkway

CidadeREDWOOD CITY

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal94065

Telefone16506888803

Sitehttps://www.corcept.com/

Código da empresaCORT

Data de listagemApr 15, 2004

CEODr. Joseph K. Belanoff, M.D.

Executivos da empresa Corcept Therapeutics Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Joseph K. Belanoff, M.D.

President, Chief Executive Officer, Co-Founder, Director

2.98M

-0.02%

Mr. James N. (Jim) Wilson

Independent Chairman of the Board

2.35M

+5.82%

Mr. David L. Mahoney

Independent Director

1.26M

--

Dr. Hazel Hunt, Ph.D.

Chief Scientific Officer

183.41K

+54.67%

Mr. Sean Maduck

President - Corcept Endocrinology

97.60K

--

Mr. Gary Charles (Charlie) Robb

Chief Business Officer, Secretary

36.03K

+0.69%

Mr. Atabak Mokari

Chief Financial Officer, Treasurer

14.32K

+1.82%

Mr. Joseph Douglas Lyon

Chief Accounting and Technology Officer

10.28K

--

Mr. William Guyer, Pharm.D.

Chief Development Officer

5.29K

--

Mr. Gregg Huber Alton, J.D.

Independent Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Joseph K. Belanoff, M.D.

President, Chief Executive Officer, Co-Founder, Director

2.98M

-0.02%

Mr. James N. (Jim) Wilson

Independent Chairman of the Board

2.35M

+5.82%

Mr. David L. Mahoney

Independent Director

1.26M

--

Dr. Hazel Hunt, Ph.D.

Chief Scientific Officer

183.41K

+54.67%

Mr. Sean Maduck

President - Corcept Endocrinology

97.60K

--

Mr. Gary Charles (Charlie) Robb

Chief Business Officer, Secretary

36.03K

+0.69%

Detalhamento da receita

Sem dados

Sem dados

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: dom, 17 de ago

Investidores

Tipos de investidores

Investidores

Proporção

BlackRock Institutional Trust Company, N.A.

10.74%

The Vanguard Group, Inc.

9.17%

Ingalls & Snyder LLC (Asset Management)

7.33%

Renaissance Technologies LLC

5.95%

Baker (George Leonard Jr.)

5.04%

Outro

61.78%

Investidores

Proporção

BlackRock Institutional Trust Company, N.A.

10.74%

The Vanguard Group, Inc.

9.17%

Ingalls & Snyder LLC (Asset Management)

7.33%

Renaissance Technologies LLC

5.95%

Baker (George Leonard Jr.)

5.04%

Outro

61.78%

Tipos de investidores

Investidores

Proporção

Investment Advisor

39.89%

Investment Advisor/Hedge Fund

23.01%

Individual Investor

11.62%

Hedge Fund

8.65%

Research Firm

1.60%

Pension Fund

1.21%

Sovereign Wealth Fund

0.96%

Bank and Trust

0.44%

Venture Capital

0.25%

Outro

12.37%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

771

80.09M

76.01%

-11.97M

2025Q2

740

96.93M

91.97%

-8.00M

2025Q1

746

97.45M

92.10%

-9.12M

2024Q4

673

98.29M

93.20%

-10.89M

2024Q3

625

101.82M

97.42%

-10.51M

2024Q2

589

103.22M

99.09%

-12.69M

2024Q1

582

107.51M

103.94%

+2.98M

2023Q4

555

98.31M

95.40%

-4.22M

2023Q3

540

96.45M

94.14%

-5.68M

2023Q2

523

94.35M

92.83%

-12.18M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

BlackRock Institutional Trust Company, N.A.

11.31M

10.74%

-1.71M

-13.12%

Jun 30, 2025

The Vanguard Group, Inc.

9.66M

9.17%

-301.38K

-3.03%

Jun 30, 2025

Ingalls & Snyder LLC (Asset Management)

7.72M

7.33%

-19.66K

-0.25%

Jun 30, 2025

Renaissance Technologies LLC

6.27M

5.95%

+123.37K

+2.01%

Jun 30, 2025

Baker (George Leonard Jr.)

5.31M

5.04%

--

Apr 17, 2025

Parallel Advisors, LLC

3.87M

3.67%

-101.29K

-2.55%

Jun 30, 2025

Belanoff (Joseph K)

2.98M

2.83%

-615.00

-0.02%

Jul 17, 2025

State Street Global Advisors (US)

2.97M

2.82%

-434.35K

-12.77%

Jun 30, 2025

Wilson (James N)

2.35M

2.23%

+129.14K

+5.82%

Apr 17, 2025

Dimensional Fund Advisors, L.P.

2.09M

1.98%

-50.99K

-2.39%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: seg, 6 de out

Nome

Proporção

Invesco S&P SmallCap Health Care ETF

4.45%

Formidable ETF

3.5%

SPDR S&P Pharmaceuticals ETF

3.21%

First Trust NYSE Arca Biotechnology Index Fund

3.15%

iShares U.S. Pharmaceuticals ETF

3.06%

Invesco S&P SmallCap Momentum ETF

2.53%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.34%

Invesco Pharmaceuticals ETF

2.16%

Pacer US Small Cap Cash Cows Growth Leaders ETF

2.1%

Invesco S&P SmallCap 600 Pure Growth ETF

1.52%

Ver Mais

Invesco S&P SmallCap Health Care ETF

Proporção4.45%

Formidable ETF

Proporção3.5%

SPDR S&P Pharmaceuticals ETF

Proporção3.21%

First Trust NYSE Arca Biotechnology Index Fund

Proporção3.15%

iShares U.S. Pharmaceuticals ETF

Proporção3.06%

Invesco S&P SmallCap Momentum ETF

Proporção2.53%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporção2.34%

Invesco Pharmaceuticals ETF

Proporção2.16%

Pacer US Small Cap Cash Cows Growth Leaders ETF

Proporção2.1%

Invesco S&P SmallCap 600 Pure Growth ETF

Proporção1.52%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados